Imidazoline derivatives: a patent review (2006 – present)

Bibliography

• Szabo B. Imidazoline antihypertensive drugs: a critical review on their mechanism of action. Pharmacol Therapeut 2002;93(1):1-35
   PubMedGoogle Scholar
• Jin J, Kittanakom S, Wong V, Interaction of the mu-opioid receptor with GPR177 (Wntless) inhibits Wnt secretion: potential implications for opioid dependence. BMC Neurosci 2010;11:33
   PubMedGoogle Scholar
• Oertel BG, Schmidt R, Schneider A, The mu-opioid receptor gene polymorphism 118A > G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genom 2006;16(9):625-36
   PubMedGoogle Scholar
• Goodman AJ, Le Bourdonnec B, Dolle RE. Mu opioid receptor antagonists: recent developments. Chem Med Chem 2007;2(11):1552-70
   Google Scholar
• Pasternak G, Pan YX. Mu opioid receptors in pain management. Acta Anaesthesiol Taiwan 2011;49(1):21-5
   PubMedGoogle Scholar
• Ray LA, Barr CS, Blendy JA, The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res 2012;36(3):385-94
   PubMed Web of Science ®Google Scholar
• Phan NQ, Bernhard JD, Luger TA, Antipruritic treatment with systemic mu-opioid receptor antagonists: a review. J Am Acad Dermatol 2010;63(4):680-8
   PubMed Web of Science ®Google Scholar
• Ingram SL, Traynor JR. Role of protein kinase C in functional selectivity for desensitization at the mu-opioid receptor: from pharmacological curiosity to therapeutic potential. Brit J Pharmacol 2009;158(1):154-6
   PubMedGoogle Scholar
• Merla B, Oberboersch S, Sundermann B, Substituted imidazoline derivatives. WO2007079927; 2007
   Google Scholar
• Galley G, Groebke Zbinden K, Norcross R, 2-imidazolines having a good affinity to the trace amine associated receptors (TAARs). WO2009003868; 2009
   Google Scholar
• Miller GM. Avenues for the development of therapeutics that target trace amine associated receptor 1 (TAAR1). J Med Chem 2012;55(5):1809-14
   PubMed Web of Science ®Google Scholar
• Miller GM. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem 2011;116(2):164-76
   PubMed Web of Science ®Google Scholar
• Sotnikova TD, Zorina OI, Ghisi V, Trace amine associated receptor 1 and movement control. Parkinsonism Relat D 2008;14(Suppl 2):S99-102
   PubMedGoogle Scholar
• Borowsky B, Adham N, Jones KA, Trace amines: identification of a family of mammalian G protein-coupled receptors. P Natl Acad Sci USA 2001;98(16):8966-71
   PubMed Web of Science ®Google Scholar
• Bunzow JR, Sonders MS, Arttamangkul S, Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 2001;60(6):1181-8
   PubMed Web of Science ®Google Scholar
• Horie K, Obika K, Foglar R, Selectivity of the imidazoline alpha-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned alpha(1)-adrenoceptor subtypes. Brit J Pharmacol 1995;116(1):1611-18
   PubMedGoogle Scholar
• Jain KS, Bariwal JB, Kathiravan MK, Recent advances in selective alpha1-adrenoreceptor antagonists as antihypertensive agents. Bioorgan Med Chem 2008;16(9):4759-800
   PubMedGoogle Scholar
• Sorbera LA, Castaner J. Dabuzalgron hydrochloride. Treatment of urinary incontinence, alpha(1A/1L)-Adrenoceptor partial agonist. Drug Future 2004;29(3):216-19
   Google Scholar
• Muramatsu I, Kitagawa H. Imidazoline derivative. WO2009128479; 2009
   Google Scholar
• Takahashi T, Kanakubo N, Kobayashi T, Imidazoline derivatives. WO2012008565; 2012
   Google Scholar
• Ford A, Williams TJ, Blue DR, Alpha-1-adrenoceptor classification - sharpening occam's razor. Trends Pharmacol Sci 1994;15(6):167-70
   PubMedGoogle Scholar
• Chern JW, Tao PL, Yen MH, Studies on quinazolines. 5. 2,3-dihydroimidazo 1,2-c quinazoline derivatives - a novel class of potent and selective alpha(1)-adrenoceptor antagonists and antihypertensive agents. J Med Chem 1993;36(15):2196-207
   PubMedGoogle Scholar
• Horn G. Method and composition which reduces stimulation of muscles which dilate the eye. US2006211753; 2006
   Google Scholar
• Garst ME, Dolby LJ, Esfandiari S, Method of making imidazole-2-thiones. WO2006062890; 2006
   Google Scholar
• Devita VT, Schein PS. The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med 1973;288(19):998-1006
   PubMedGoogle Scholar
• Maes M, Meltzer HY. The serotonin hypothesis of major depression. Raven Press; New York: 1995
   Google Scholar
• Maes M, Van Gastel A, Delmeire L, Decreased platelet alpha-2 adrenoceptor density in major depression: effects of tricyclic antidepressants and fluoxetine. Biol Psychiat 1999;45(3):278-84
   PubMedGoogle Scholar
• Costagliola C, Parmeggiani F, Semeraro F, Selective serotonin reuptake inhibitors: a Review of its effects on intraocular pressure. Curr Neuropharmacol 2008;6(4):293-310
   PubMedGoogle Scholar
• Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed-patients treated with serotonin reuptake inhibitors. Arch Gen Psychiat 1994;51(3):248-51
   PubMedGoogle Scholar
• Perez V, Gilaberte I, Faries D, Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349(9065):1594-7
   PubMed Web of Science ®Google Scholar
• Svensson T, Langger S, Langer SZ. Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor. WO2006083204; 2006
   Google Scholar
• Zhang P, Pennell AMK, Li L, Oxo-imidazolidines as modulators of chemokine receptors. US2008269280; 2008
   Google Scholar
• Haga Y, Moriya M, Takahashi T. 2. Aryl imidazoline derivatives. WO2010123150; 2010
   Google Scholar
• Mendieta L, Tarrago T, Giralt E. Recent patents of dipeptidyl peptidase IV inhibitors. Expert Opin Ther Pat 2011;21(11):1693-741
   PubMed Web of Science ®Google Scholar
• Yang B CN, Hu Y CN, He Q CN, New imidazoline-2,4-diketone derivative as dipeptidyl peptidase IV inhibitor used for preventing type II diabetes or regulating blood sugar level. CN101875636; 2010
   Google Scholar
• Ghiso J, Frangione B. Amyloidosis and Alzheimer's disease. Adv Drug Deliver Rev 2002;54(12):1539-51
   PubMedGoogle Scholar
• Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001;32(2):177-80
   PubMed Web of Science ®Google Scholar
• Hardy J, Duff K, Hardy KG, Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat Neurosci 1998;1(5):355-8
   PubMedGoogle Scholar
• Roses AD. Alzheimer diseases: a model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases. Am J Med Genet 1998;81(1):49-57
   PubMedGoogle Scholar
• Ray WJ, Yao M, Mumm J, Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch. J Biol Chem 1999;274(51):36801-7
   PubMedGoogle Scholar
• Ghosh AK, Brindisi M, Tang J. Developing beta-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem 2012;120(Suppl 1):71-83
   PubMed Web of Science ®Google Scholar
• Arbel M, Solomon B. A novel immunotherapy for Alzheimer's disease: antibodies against the beta-secretase cleavage site of APP. Curr Alzheimer Res 2007;4(4):437-45
   PubMedGoogle Scholar
• Vassar R. Beta-secretase (BACE) as a drug target for Alzheimer's disease. Adv Drug Deliv Rev 2002;54(12):1589-602
   PubMed Web of Science ®Google Scholar
• Berg S, Hoegdin K, Kihlstroem J, Amino-imidazolines and their use as a medicament for treating cognitive impairment, Alzheimer disease, neurodegeneration and dementia. WO2007145568; 2007
   Google Scholar
• Zhou P, Bernotas RC, Li Y, 2-Amino-5-piperidinylimidazolone compounds and use thereof for (insert beta symbol)-secretase modulation. WO2007078813; 2007
   Google Scholar
• Quagliato DA, Andrae PM, Fan Y. Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase. US2007203116; 2007
   Google Scholar
• Berg S, Burrows J, Chessari G, Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia. WO2007058602; 2007
   Google Scholar
• Albert J, Arnold J, Chessari G, Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia. WO2007058601; 2007
   Google Scholar
• Lane DP, Crawford LV. T-antigen is bound to a host protein in sv40-transformed cell. Nature 1979;278(5701):261-3
   PubMed Web of Science ®Google Scholar
• Linzer DIH, Levine AJ. Characterization of a 54k Dalton cellular sv40 tumor-antigen present in sv40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17(1):43-52
   PubMed Web of Science ®Google Scholar
• Khoury K, Popowicz GM, Holak TA, The p53-MDM2/MDMX axis - A chemotype perspective. Medchemcomm 2011;2(4):246-60
   PubMedGoogle Scholar
• Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2(8):594-604
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti GP, Olson DC, The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69(7):1237-45
   PubMed Web of Science ®Google Scholar
• Haupt Y, Maya R, Kazaz A, Mdm2 promotes the rapid degradation of p53. Nature 1997;387(6630):296-9
   PubMed Web of Science ®Google Scholar
• Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. Febs Lett 1997;420(1):25-7
   PubMed Web of Science ®Google Scholar
• Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387(6630):299-303
   PubMed Web of Science ®Google Scholar
• Oliner JD, Pietenpol JA, Thiagalingam S, Oncoprotein mdm2 conceals the activation domain of tumor suppressor-p53. Nature 1993;362(6423):857-60
   PubMed Web of Science ®Google Scholar
• Tao WK, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. P Natl Acad Sci USA 1999;96(6):3077-80
   PubMedGoogle Scholar
• Millard M, Pathania D, Grande F, Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update. Curr Pharm Design 2011;17(6):536-59
   PubMedGoogle Scholar
• Dickens MP, Fitzgerald R, Fischer PM. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin Cancer Biol 2010;20(1):10-18
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303(5659):844-8
   PubMed Web of Science ®Google Scholar
• Fotouhi N, Haley GJ, Simonsen KB, Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments. WO2006097261-A1; 2006
   Google Scholar
• Fotouhi N, Haley GJ, Simonsen KB, Chiral cis-imidazolines. US2009143364; 2009
   Google Scholar
• Ding Q, Graves BJ, Kong N, 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents. WO2007063013; 2007
   Google Scholar
• Bartkovitz DJ, Cai J, Chu X, Chiral cis-imidazolines. WO2009047161; 2009
   Google Scholar
• Patton JT, Mayo LD, Singhi AD, Levels of HdmX expression dictate the sensitivity of normal and transformed cells to nutlin-3. Cancer Res 2006;66(6):3169-76
   PubMed Web of Science ®Google Scholar
• Wade M, Wong ET, Tang M, Hdmx modulates the outcome of P53 activation in human tumor cells. J Biol Chem 2006;281(44):33036-44
   PubMedGoogle Scholar
• Hu B, Gilkes DM, Farooqi B, MDMX overexpression prevents p53 activation by the MDM2 inhibitor nutlin. J Biol Chem 2006;281(44):33030-5
   PubMed Web of Science ®Google Scholar
• Xia M, Knezevic D, Tovar C, Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 2008;7(11):1604-12
   PubMed Web of Science ®Google Scholar
• Marrelli M, Conforti F, Statti GA, Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4. Curr Med Chem 2011;18(20):3035-81
   PubMedGoogle Scholar
• Tron GC, Pirali T, Sorba G, Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 2006;49(11):3033-44
   PubMed Web of Science ®Google Scholar
• Simoni D, Grisolia G, Giannini G, Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. J Med Chem 2005;48(3):723-36
   PubMedGoogle Scholar
• Leblanc R, Dickson J, Brown T, Synthesis and cytotoxicity of epoxide and pyrazole analogs of the combretastatins. Bioorgan Med Chem 2005;13(21):6025-34
   PubMedGoogle Scholar
• Bhat BA, Dhar KL, Puri SC, Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents. Bioorg Med Chem Lett 2005;15(12):3177-80
   PubMed Web of Science ®Google Scholar
• Hu Y, Xue N, Yang X, Indole substituted imidazoline-2-ketone derivative or its salt is useful for preparing anti-neoplastic drugs, is new. ZL200710071435; 2007
   Google Scholar
• Hu Y, Xue N, Yang X, New aryl substituted imidazoline-2-ketone derivative for preparing antitumor medicine. ZL200710071439; 2007
   Google Scholar
• Baltimore D. Discovering NF-kappaB. Csh Perspect Biol 2009;1(1):a000026
   Google Scholar
• Kwak J-H, Jung J-K, Lee H. Nuclear factor-kappa B inhibitors; a patent review (2006-2010). Expert Opin Ther Pat 2011;21(12):1897-910
   PubMed Web of Science ®Google Scholar
• Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994;10:405-55
   PubMedGoogle Scholar
• Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann Ny Acad Sci 2005;1056:218-33
   PubMed Web of Science ®Google Scholar
• Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene 2006;25(51):6758-80
   PubMed Web of Science ®Google Scholar
• Breccia M, Alimena G. NF-kappaB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opin Ther Targets 2010;14(11):1157-76
   PubMed Web of Science ®Google Scholar
• Tanaka K, Babic I, Nathanson D, Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov 2011;1(6):524-38
   PubMed Web of Science ®Google Scholar
• Mukogawa T, Koyama F, Tachibana M, Adenovirus-mediated gene transduction of truncated I kappa B alpha enhances radiosensitivity in human colon cancer cells. Cancer Sci 2003;94(8):745-50
   PubMedGoogle Scholar
• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441(7092):431-6
   PubMed Web of Science ®Google Scholar
• Uetsuka H, Haisa M, Kimura M, Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 2003;289(1):27-35
   PubMedGoogle Scholar
• Lin L, Ghosh S. A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit. Mol Cell Biol 1996;16(5):2248-54
   PubMed Web of Science ®Google Scholar
• May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998;19(2):80-8
   PubMedGoogle Scholar
• Baeuerle PA, Baltimore D, NF-kappa B. Ten years after. Cell 1996;87(1):13-20
   PubMed Web of Science ®Google Scholar
• Ahn KS, Aggarwal BB. Transcription factor NF-kappa B - A sensor for smoke and stress signals. 2005;1056:218-33
   Google Scholar
• Olivier S, Close P, Castermans E, Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature. Mol Pharmacol 2006;69(5):1615-23
   PubMedGoogle Scholar
• Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 1999;18(49):6896-909
   PubMedGoogle Scholar
• Tepe JJ, Tepe J. Nuclear factor-kappa B inhibitors and uses thereof. WO2007133790; 2007
   Google Scholar
• Hamby J, Tepe J. Substituted imidazoline compounds. WO2009048586; 2009
   Google Scholar
• De Luca L. Naturally occurring and synthetic imidazoles: their chemistry and their biological activities. Curr Med Chem 2006;13(1):1-23
   PubMedGoogle Scholar
• Huang Z. New imidazoline, pyrrolidine containing compound for use in preparing pharmaceutical composition for treating and/or preventing infectious diseases. ZL200810128939; 2008
   Google Scholar